StockData

IM Cannabis vs Intercure

IMCC and INCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCC and INCR compare

Intercure grew revenue faster over the last twelve months (13.1% versus 1.3% for IM Cannabis).

Intercure keeps more of each dollar of sales as profit, with a net margin of −13.2% compared with −20.7% at IM Cannabis.

IM Cannabis scores higher on the StockData Score (4 against 3 for Intercure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCCINCR
Size and price
Share price$0.495$3.79
Change, 1 year−98.7%−44.3%
Change, 5 years−100.0%−90.4%
Beta (5Y)1.82–
Employees95–
StockData Score
Total score4 (better)3
Valuation score00
Growth score11
Performance score22
Health score1 (better)0
Dividend score00
Growth
Revenue growth (TTM)1.3%13.1% (better)
Revenue growth, 5Y average28.1%33.0% (better)
Profitability
Gross margin17.7% (better)12.3%
Operating margin−21.2%−10.1% (better)
Net margin−20.7%−13.2% (better)
FCF margin8.6% (better)4.9%
Return on equity–−9.0%
Return on invested capital−82.3%−4.0% (better)
Financial health
Debt / equity–0.49
Interest coverage−3.3×–
Current ratio0.56–
Piotroski F-score45 (better)
Ownership
Held by institutions–0.22%
Held by insiders0.00%30.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.